
|Articles|April 26, 2004
Proprietary sustained-release dexamethasone implant shows promise for treating persistent cystoid macular edema
Results of a controlled Phase I/II study show that the bioerodable, sustained-release,dexamethasone implant (Posurdex, Allergan) results in a statistically significantincrease in ETDRS standardized visual acuity in eyes with persistent cystoidmacular edema (CME), said Mark S. Blumenkranz, MD.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Eyes on May 2026: A month of durable therapies, a regulatory reversal, and rethought echanisms
2
Reasoning prompts sharpen multimodal AI on bilingual ophthalmology exam questions
3
TECNIS PureSee IOL launches in US following FDA approval for cataract surgery
4
Beyond the Walls: Leading with love, loyalty, and a team first philosophy with Vance Thompson, MD
5





















